Baidu
map

国家药监局部署工作重点 要烧审批制度改革这把火

2018-04-18 佚名 国家药监局

4月17日,国家药品监督管理局召开干部大会,深入贯彻落实党中央、国务院决策部署,动员部署机构改革工作,研究谋划药品监管事业改革发展思路和举措。国家药品监督管理局党组书记、副局长李利发表讲话,国家药品监督管理局局长焦红主持。李利指出,深化党和国家机构改革,是以习近平同志为核心的党中央作出的重大决策,是新时代推进国家治理体系和治理能力现代化的一项重大部署。广大干部职工要充分认识这次机构改革的重要性、必

4月17日,国家药品监督管理局召开干部大会,深入贯彻落实党中央、国务院决策部署,动员部署机构改革工作,研究谋划药品监管事业改革发展思路和举措。国家药品监督管理局党组书记、副局长李利发表讲话,国家药品监督管理局局长焦红主持。

李利指出,深化党和国家机构改革,是以习近平同志为核心的党中央作出的重大决策,是新时代推进国家治理体系和治理能力现代化的一项重大部署。广大干部职工要充分认识这次机构改革的重要性、必要性,切实把思想和行动统一到中央决策部署上来,自觉增强“四个意识”,坚决维护以习近平同志为核心的党中央权威,扎实做好国家药品监督管理局组建工作,确保机构职能及时有序调整到位。

李利强调,面对新时代、新形势、新要求,要始终坚持以习近平新时代中国特色社会主义思想为引领,坚持“稳中求进”工作总基调,认真研究和解决改革发展中出现的新情况、新问题,着力创新监管方式,提升监管能力,防控安全风险,确保公众用药安全有效,促进药品高质量发展。要守住底线,强化全过程监管,加强安全隐患排查,提升应急处置能力,严防严管严控药品安全风险。要追求高线,推进药品标准与国际接轨,增强医药产业创新能力,建立完善的研发体系,加强药品专利保护,促进仿制药研发,推动药品高质量发展。要依法治药,进一步完善法律法规体系,坚持从严执法,提高药品监管法治化水平。要夯实基础,加强职业化审评员检查员队伍建设,强化阳光监管,创新智慧监管,不断增强药品监管能力。要凝聚合力,落实企业主体责任、地方党委政府领导责任、药监部门监管责任,引导社会各界共同参与,构建药品安全社会共治格局。

李利要求,要全面加强党的建设,推动全面从严治党向纵深发展,提升党组织的凝聚力和战斗力,为落实机构改革工作目标,为药监事业改革发展提供坚强政治保证。要坚持把党的政治建设摆在首位,坚决维护党中央集中统一领导,扎实推进党的思想政治建设,提升基层党组织战斗力。要坚持加强学习、勤勉敬业、团结和谐、善谋实干、创新有为,打造一支想干事、能干事、干成事、不出事的药监干部队伍。要全力配合中央巡视工作,认真落实中央八项规定,持之以恒推动党风廉政建设和反腐败工作取得新成效。

焦红对下一阶段重点工作进行了安排。一是要深化药品医疗器械审评审批制度改革。抓紧开展法律法规和配套制度的制修订,鼓励创新药品医疗器械及时进入市场,优化审评审批流程,提高审评质量和效率,继续推进仿制药质量和疗效一致性评价。二是要加强药品医疗器械化妆品的日常监管。继续坚持风险管理的理念,坚持问题导向,强化高风险产品的监管,加强现场检查,切实压实企业主体责任,进一步加强监督抽验和不良事件监测工作,严防严管严控风险隐患。三是要进一步加大违法违规行为打击力度,重拳出击、重典治乱,重点打击依托互联网制假售假行为,对不法分子持续保持高压态势。四是要积极推进“智慧监管”、“阳光监管”,加快推进药品、医疗器械、化妆品数据库建设,大力推进行政许可电子化工作,逐步建立品种档案库,加大政务信息公开力度,定期公布抽检、检查、处罚等监管信息,提高监管透明度。五是要加强专业化队伍建设。加强职业化审评员检查员队伍建设。强化对检查员的系统培训和管理,拓展检查员职业发展空间,把专业技术人才留在监管第一线。

焦红提出三点要求。一是善谋长远。中层领导干部要具备战略眼光和国际视野,提高工作水平。加强国际合作,要推进监管科学研究,跟踪研究产业、科技发展动态,做大做强技术支撑体系。要结合“十三五”规划的实施,加强能力建设,要勤于学习,成为监管业务的专家学者。二是夯实基础。每项工作都要善始善终、善作善为。直属单位是药监工作的重要支撑,要积极主动作为。三是加强管理。要管好人、管好事、讲规矩,牢记公职人员的身份定位。在业务上要强化质量内控,做到闭环管理。要注意倾听企业呼声,营造“亲”“清”新型政商关系。

机关各司局副处级以上干部、各直属单位班子成员参加了会议

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1937807, encodeId=c69e193e8071c, content=<a href='/topic/show?id=25d14e9162f' target=_blank style='color:#2F92EE;'>#工作重点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47916, encryptionId=25d14e9162f, topicName=工作重点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Tue Mar 05 05:28:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301573, encodeId=b00213015e352, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Apr 19 23:28:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405828, encodeId=b71d140582831, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Apr 19 23:28:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429141, encodeId=b534142914138, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Thu Apr 19 23:28:00 CST 2018, time=2018-04-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1937807, encodeId=c69e193e8071c, content=<a href='/topic/show?id=25d14e9162f' target=_blank style='color:#2F92EE;'>#工作重点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47916, encryptionId=25d14e9162f, topicName=工作重点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Tue Mar 05 05:28:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301573, encodeId=b00213015e352, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Apr 19 23:28:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405828, encodeId=b71d140582831, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Apr 19 23:28:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429141, encodeId=b534142914138, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Thu Apr 19 23:28:00 CST 2018, time=2018-04-19, status=1, ipAttribution=)]
    2018-04-19 xuyu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1937807, encodeId=c69e193e8071c, content=<a href='/topic/show?id=25d14e9162f' target=_blank style='color:#2F92EE;'>#工作重点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47916, encryptionId=25d14e9162f, topicName=工作重点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Tue Mar 05 05:28:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301573, encodeId=b00213015e352, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Apr 19 23:28:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405828, encodeId=b71d140582831, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Apr 19 23:28:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429141, encodeId=b534142914138, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Thu Apr 19 23:28:00 CST 2018, time=2018-04-19, status=1, ipAttribution=)]
    2018-04-19 chg122
  4. [GetPortalCommentsPageByObjectIdResponse(id=1937807, encodeId=c69e193e8071c, content=<a href='/topic/show?id=25d14e9162f' target=_blank style='color:#2F92EE;'>#工作重点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47916, encryptionId=25d14e9162f, topicName=工作重点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Tue Mar 05 05:28:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301573, encodeId=b00213015e352, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Apr 19 23:28:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405828, encodeId=b71d140582831, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Apr 19 23:28:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429141, encodeId=b534142914138, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Thu Apr 19 23:28:00 CST 2018, time=2018-04-19, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map